Related Experiment Video
Updated: Jul 7, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Antithrombotic activity of heparin-ATP complex
T Yu Obergan1, L A Lyapina, V E Pastorova
1B. A. Kudryashov Laboratory of Blood Defense Systems, Biological Faculty, M. V. Lomonosov Moscow State University.
Bulletin of Experimental Biology and Medicine
|January 30, 2008
Summary
High-molecular-weight heparin and ATP complex prevents blood clots. Injections boost blood clot breakdown and anticoagulant activity while reducing platelet aggregation.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Thrombus formation is a critical issue in cardiovascular diseases.
- Heparin and adenosine triphosphate (ATP) are known for their roles in coagulation and energy metabolism.
Purpose of the Study:
- To investigate the antithrombotic potential of a high-molecular-weight heparin and ATP complex.
- To evaluate the effects of repeated intramuscular administration of this complex on blood properties.
Main Methods:
- A complex of high-molecular-weight heparin and ATP was prepared.
- The complex was administered via repeated intramuscular injections.
- Assays were performed to measure thrombus formation, fibrinolytic activity, nonenzymatic fibrinolysis, plasma anticoagulant activity, and platelet aggregation.
Main Results:
- The heparin-ATP complex effectively prevented thrombus formation in blood flow.
- Repeated injections significantly increased total fibrinolytic activity and nonenzymatic fibrinolysis.
- Plasma anticoagulant activity was enhanced, and platelet aggregation was significantly reduced.
Conclusions:
- The high-molecular-weight heparin and ATP complex exhibits significant antithrombotic properties.
- This complex demonstrates potential for therapeutic applications in managing thrombotic disorders.
- Further research is warranted to explore its clinical efficacy and safety profile.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...